Psychedelic Stocks Just Went Mainstream

Submitted by QTR’s Fringe Finance

Donald Trump just did something that would have sounded borderline impossible a couple of years ago: he signed an executive order aimed at accelerating research and access to psychedelic therapies, backing it with $50 million in federal funding and directing regulators to remove barriers that have long kept this entire category stuck on the sidelines.

This has been a key prediction in my thesis for psychedelic stocks that I’ve laid out over time. First, in January 2025, calling the psychedelic names “stocks to watch” for the year. Then, in July 2025, urging patience in these positions: Being Early—And Patient—In Psychedelics

Then again naming psychedelic names to my “stocks to watch” for 2026 and even going so far as to name the sector my “best idea” for 2026: My “Best Idea” Sector For 2026

Today I’ll discuss what, for me, remains the most prudent way to get and keep long-term exposure to the sector, and where I think things go after this morning’s rally.

Trump’s administration framed the move as part of a broader attempt to confront the mental health crisis, particularly among veterans, while signaling that agencies like the FDA should dramatically speed up review timelines for promising treatments.

The focus, at least initially, includes ibogaine, a compound with a controversial safety profile but growing interest for its potential in treating addiction and trauma.

Alongside him were figures like Robert F. Kennedy Jr. and Joe Rogan, both of whom have been outspoken advocates for these therapies, underscoring how quickly this conversation has moved from the fringe into the mainstream. There are still real concerns from scientists about safety, trial rigor, and whether the process could move too fast, but the direction is unmistakable: the federal government is no longer ignoring psychedelics, it is actively engaging with them.

And if you have been reading me for the last year, none of this should feel surprising. At the beginning of 2025, I laid out what I thought was coming: a convergence between science, sentiment, and politics that could finally legitimize an industry that had been written off for decades.

I was not pretending the timing would be perfect or that the stocks would go straight up, in fact, I explicitly said the opposite. These were always going to be volatile, early stage, cash burning companies operating in one of the most regulation sensitive industries on the planet.

What mattered was not the quarter to quarter performance. What mattered was whether the world would eventually start taking this category seriously. That was the first part of the bet. The next is clinical data.

And along the way, the market did exactly what it tends to do with misunderstood themes. It tested conviction. The ETF held up relatively well, individual names stumbled, sentiment wavered, and most investors moved on, filing the entire space under maybe someday or probably never. But the thesis was never about clean execution in year one. It was about whether a regulatory shift, any regulatory shift, could change the entire trajectory of the space. Because in something like psychedelics, policy is not just a factor, it is the factor.

That is why, when I revisited the idea in January 2026, I framed it as one of the most mispriced areas of the market. Not because the science was a mystery, but because the perception was broken. The consensus view had already written the story: the FDA had shut it down, politics would never allow it, and the stigma was too entrenched to overcome.

🔥 50% OFF FOR LIFE: Using this coupon entitles you to 50% off an annual subscription to Fringe Finance for life: Get 50% off forever

What makes this moment different is that it is no longer theoretical. You now have federal dollars being allocated, timelines being discussed in terms of weeks instead of years, and high level officials openly framing psychedelics as part of the solution to a national health crisis. That does not guarantee success for any individual company, and it does not eliminate the very real risks around clinical trials, commercialization, or safety. Some of these names will fail. Some will dilute shareholders into the ground. That is the nature of early stage biotech.

But the broader direction of the space is what matters, and that direction is changing in a way that is hard to ignore.

The deeper reason I have stayed bullish, though, has never just been about the market opportunity. It is about what these compounds actually represent. The current mental health model leaves an enormous number of people behind, and most treatments are designed around chronic, daily use. Psychedelics flip that model on its head. They are not ‘take this forever’ drugs. In many cases, they are structured as limited, guided interventions that can produce durable effects. That alone makes them disruptive, not just commercially, but philosophically. And having experienced them myself in a deliberate, structured way, I do not view this as abstract or hypothetical. I have seen the difference. I have felt the shift. And I know how profound it can be when these tools are used correctly.

What is happening now does not mean the story is over. If anything, it means it is just getting started. We are moving out of the phase where this is dismissed outright and into the phase where serious institutions are forced to engage with it. That is where things tend to accelerate.

This note, published on my blog this week, has my preferred way to gain exposure to the psychedelic sector.

QTR’s Disclaimer: Please read my full legal disclaimer on my About page here. This post represents my opinions only. In addition, please understand I am an idiot and often get things wrong and lose money. I may own or transact in any names mentioned in this piece at any time without warning. Contributor posts and aggregated posts have been hand selected by me, have not been fact checked and are the opinions of their authors. They are either submitted to QTR by their author, reprinted under a Creative Commons license with my best effort to uphold what the license asks, or with the permission of the author.

This is not a recommendation to buy or sell any stocks or securities, just my opinions. I often lose money on positions I trade/invest in. I may add any name mentioned in this article and sell any name mentioned in this piece at any time, without further warning. None of this is a solicitation to buy or sell securities. I may or may not own names I write about and are watching. Sometimes I’m bullish without owning things, sometimes I’m bearish and do own things. Just assume my positions could be exactly the opposite of what you think they are just in case. If I’m long I could quickly be short and vice versa. I won’t update my positions. All positions can change immediately as soon as I publish this, with or without notice and at any point I can be long, short or neutral on any position. You are on your own. Do not make decisions based on my blog. I exist on the fringe. If you see numbers and calculations of any sort, assume they are wrong and double check them. I failed Algebra in 8th grade and topped off my high school math accolades by getting a D- in remedial Calculus my senior year, before becoming an English major in college so I could bullshit my way through things easier.

The publisher does not guarantee the accuracy or completeness of the information provided in this page. These are not the opinions of any of my employers, partners, or associates. I did my best to be honest about my disclosures but can’t guarantee I am right; I write these posts after a couple beers sometimes. I edit after my posts are published because I’m impatient and lazy, so if you see a typo, check back in a half hour. Also, I just straight up get shit wrong a lot. I mention it twice because it’s that important.